(Q37877269)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21595603%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

review article

1 reference

title

Stimulating natural killer cells to protect against cancer: recent developments (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21595603%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21595603%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

Amy Gillgrass

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21595603%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

publication date

1 May 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21595603%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Clinical Immunology

1 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21595603%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21595603%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21595603%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

367-382

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21595603%20AND%20SRC:MED&resulttype=core&format=json

Interferons, immunity and cancer immunoediting

1 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

The three Es of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

The immunobiology of cancer immunosurveillance and immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

„Natural”︁ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

The trafficking of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Functions of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Tumor growth decreases NK and B cells as well as common lymphoid progenitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Tumor growth impedes natural-killer-cell maturation in the bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

NK cells and cancer immunosurveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

The polarization of immune cells in the tumour environment by TGFbeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Safety and immunologic effects of IL-15 administration in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

FimH can directly activate human and murine natural killer cells via TLR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Human natural killer cell development and biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Functional subsets of mouse natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Adaptive immune features of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Immune memory redefined: characterizing the longevity of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Natural killer cells: detectors of stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

In search of the 'missing self': MHC molecules and NK cell recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

NKG2D ligands in tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Oncogenic stress sensed by the immune system: role of natural killer cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

NKG2D function protects the host from tumor initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

The DNA damage response, immunity and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Tumor immunoediting by NKp46.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

In vivo natural killer cell activities revealed by natural killer cell-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Perforin dependence of natural killer cell-mediated tumor control in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Natural killer cell immunotherapy for cancer: a new hope

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Natural Killer Cells Activated by MHC Class ILow Targets Prime Dendritic Cells to Induce Protective CD8 T Cell Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Development of a human adaptive immune system in cord blood cell-transplanted mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Development of functional human NK cells in an immunodeficient mouse model with the ability to provide protection against tumor challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

IL-15 trans-presentation promotes human NK cell development and differentiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Familial occurrence of breast cancer is associated with reduced natural killer cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor alpha chain, epithelial-to-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

The Soluble Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Natural killer cells kill human melanoma cells with characteristics of cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

A potential role for interleukin-15 in the regulation of human natural killer cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

IL-15/IL-15 receptor biology: a guided tour through an expanding universe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Dendritic cells support the in vivo development and maintenance of NK cells via IL-15 trans-presentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

How a cytokine is chaperoned through the secretory pathway by complexing with its own receptor: lessons from interleukin-15 (IL-15)/IL-15 receptor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

The interleukin-15/interleukin-15 receptor system as a model for juxtacrine and reverse signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

The IL-15 receptor {alpha} chain cytoplasmic domain is critical for normal IL-15Ralpha function but is not required for trans-presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Interleukin 15 controls both proliferation and survival of a subset of memory-phenotype CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Antiviral CD4+ memory T cells are IL-15 dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

IL-15 promotes regulatory T cell function and protects against diabetes development in NK-depleted NOD mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

IL-15 renders conventional lymphocytes resistant to suppressive functions of regulatory T cells through activation of the phosphatidylinositol 3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Interleukin-15 stimulates macrophages to activate CD4+ T cells: a role in the pathogenesis of rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Macrophage diversity and polarization: in vivo veritas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Macrophage activation and polarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Macrophage polarization in tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Activity of recombinant human interleukin-15 against tumor recurrence and metastasis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Treatment of hepatocellular carcinoma with adeno-associated virus encoding interleukin-15 superagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Interleukin-15 increases effector memory CD8+ t cells and NK Cells in simian immunodeficiency virus-infected macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Mechanisms of superior anti-tumor cytotoxic response of interleukin 15-induced lymphokine-activated killer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Combinational IL-2/IL-15 induction does not further enhance IL-15-induced lymphokine-activated killer cell cytotoxicity against human leukemia/lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Ex vivo expansion of natural killer cells for clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

IL-15R -IgG1-Fc Enhances IL-2 and IL-15 Anti-tumor Action through NK and CD8+ T Cells Proliferation and Activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Toll-like receptors and immune regulation: implications for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

A Toll-like receptor recognizes bacterial DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Development of TLR9 agonists for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

CpG oligodeoxynucleotides as immunotherapy in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

TLR3: interferon induction by double-stranded RNA including poly(I:C).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

The extrinsic RNA-sensing pathway for adjuvant immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Poly I:C-induced activation of NK cells by CD8 alpha+ dendritic cells via the IPS-1 and TRIF-dependent pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Antitumor activity of NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Role of the Innate Immune Response and Tumor Immunity Associated with Simian Virus 40 Large Tumor Antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Localized irradiation of tumors prior to synthetic dsRNA therapy enhanced the resultant anti-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Synergism between immunostimulation and prevention of surgery-induced immune suppression: an approach to reduce post-operative tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

TLR stimulation of prostate tumor cells induces chemokine-mediated recruitment of specific immune cell types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

FimH adhesin of type 1 fimbriae is a potent inducer of innate antimicrobial responses which requires TLR4 and type 1 interferon signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

The Antibody-Mediated Targeted Delivery of Interleukin-15 and GM-CSF to the Tumor Neovasculature Inhibits Tumor Growth and Metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Cutting Edge: Thymic NK Cells Develop Independently from T Cell Precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

IL-15 is an essential mediator of peripheral NK-cell homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

Membrane-Bound Interleukin (IL)-15 on Renal Tumor Cells Rescues Natural Killer Cells from IL-2 Starvation-Induced Apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

A Paracrine Loop between Tumor Cells and Macrophages Is Required for Tumor Cell Migration in Mammary Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.10.102

21 January 2018

Identifiers

DOI

10.1586/ECI.10.102

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21595603%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference